RankAlpha logo
Back to Rankings

IBIO

iBioB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
View Chart
Current thesis
The constructive view is that May warrant expiry removes a trading overhang and Q2 2026 first dosing for IBIO-600 demonstrates tangible clinical execution, which could narrow the gap between the $1.59 anchor price and the sparse target backdrop.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Despite improved liquidity, the 10-Q still flags a history of losses, negative operating cash flow, and financing dependence as factors behind prior substantial-doubt language [#10-Q-2026-02-10].
Momentum
96
Value
41
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.55 · Bull $2.10 · Bear $1.10
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $5.60
Why
Momentum96 · Δ7d -
Value41 · Δ7d +0.0
Sentiment34 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
96
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
34
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 95.6 / Value 41.1 / Sentiment 34.2

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$87.43M
Beta
1.26
Shares Out
22.49M
P/E (TTM) · Derived
-2.2
P/S (TTM)
84.55
P/FCF (TTM) · Derived
-4.85
Rev YoY
+14.3%
EPS YoY
+76.6%
Gross Margin
-
Op Margin
-4089.4%
Net Debt
-$7.7M
Current Ratio
8.39
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology